Sotatercept Gains European Approval for PAH for Use With Other Treatments
Europe approves sotatercept (Winrevair; Merck) as a combination treatment for pulmonary arterial hypertension (PAH) in World Health Organization Functional Class II to III patients, following FDA approval. Based on the Phase 3 STELLAR trial, sotatercept improved exercise capacity, reduced risk of death or clinical worsening, and improved functional class. The drug, a first activin signaling inhibitor, is administered subcutaneously every 3 weeks.
Reference News
Europe approves sotatercept (Winrevair; Merck) as a combination treatment for pulmonary arterial hypertension (PAH) in World Health Organization Functional Class II to III patients, following FDA approval. Based on the Phase 3 STELLAR trial, sotatercept improved exercise capacity, reduced risk of death or clinical worsening, and improved functional class. The drug, a first activin signaling inhibitor, is administered subcutaneously every 3 weeks.